Ikarian Capital, LLC Sage Therapeutics, Inc. Transaction History

Ikarian Capital, LLC

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 15, 2023	SELL	$37.27 - $46.57 $1.86 Million - $2.33 Million	-50,000 Reduced 73.74%	17,805 $747,000
Q4 2022 Feb 14, 2023	SELL	$32.2 - $43.61 $2.9 Million - $3.92 Million	-90,000 Reduced 57.03%	67,805 $2.59 Million
Q3 2022 Nov 14, 2022	BUY	$32.28 - $43.27 $5.09 Million - $6.83 Million	157,805 New	157,805 $6.18 Million
Q1 2022 May 13, 2022	BUY	$30.71 - $45.71 $4.88 Million - $7.26 Million	158,756 Added 174.17%	249,907 $8.27 Million
Q1 2021 May 17, 2021	BUY	$70.65 - $96.76 $1.77 Million - $2.42 Million	25,000 Added 37.79%	91,151 $6.82 Million
Q4 2020 Feb 12, 2021	SELL	$58.41 - $89.06 $2.92 Million - $4.45 Million	-50,000 Reduced 43.05%	66,151 $5.72 Million
Q3 2020 Nov 16, 2020	SELL	$41.13 - $62.45 $3.5 Million - $5.31 Million	-85,000 Reduced 42.26%	116,151 $7.1 Million
Q2 2020 Aug 14, 2020	BUY	$25.95 - $43.15 $469,695 - $781,015	18,100 Added 9.89%	201,151 $8.36 Million
Q1 2020 May 15, 2020	BUY	$26.15 - $77.24 $1.31 Million - $3.87 Million	50,051 Added 37.63%	183,051 $5.26 Million
Q4 2019 Jan 31, 2020	BUY	$60.18 - $154.77 $8 Million - $20.6 Million	133,000 New	133,000 $9.6 Million

218

46.4M

847K

188K

Ticker SAGE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 59,422,300
Market Cap $340M
Description
Sage Therapeutics, Inc., a biopharmaceutical company, develops and commercializes medicines to treat central nervous system disorders. Its lead product candidate is ZULRESSO, an intravenous formulation of brexanolone for the treatment of postpartum depression (PPD) in adults. The company's product pipeline also includes zuranolone, a neuroactive...

Get notified when there are updates to the investment portfolio of Ikarian Capital, LLC, based on Form 13F filings with the SEC.

Stay updated on Ikarian Capital, LLC with notifications on news.